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Primaquine is the only generally available anti-malarial that prevents relapse in vivax and ovale malaria, and the only
potent gametocytocide in falciparum malaria. Primaquine becomes increasingly important as malaria-endemic
countries move towards elimination, and although it is widely recommended, it is commonly not given to malaria
patients because of haemolytic toxicity in subjects who are glucose-6-phosphate dehydrogenase (G6PD) deficient
(gene frequency typically 3-30% in malaria endemic areas; >180 different genetic variants). In six decades of
primaquine use in approximately 200 million people, 14 deaths have been reported. Confining the estimate to
reports with known denominators gives an estimated mortality of one in 621,428 (upper 95% CI: one in 407,807).
All but one death followed multiple dosing to prevent vivax malaria relapse. Review of dose-response relationships
and clinical trials of primaquine in G6PD deficiency suggests that the currently recommended WHO single low dose
(0.25 mg base/kg) to block falciparum malaria transmission confers a very low risk of haemolytic toxicity.
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Primaquine is an 8-aminoquinoline, a descendant of the
first generally available synthetic anti-malarial plasmo-
quine (plasmochin, pamaquine). The 8-aminoquinolines
have unique anti-malarial properties, but they also pose
particular safety problems. This has often divided medical
opinion, and resulted in divergent treatment recommen-
dations and prescribing practices. The 8-aminoquinolines
kill mature gametocytes of Plasmodium falciparum, de-
veloping parasites of all species in the liver (causal
prophylactic activity), the dormant hypnozoites of Plas-
modium vivax and Plasmodium ovale (radical curative
activity), and they have weak asexual stage activity (very
weak for P. falciparum). The downside is that they cause
haemolysis in people who are glucose-6-phosphate de-
hydrogenase (G6PD) deficient. This X-linked abnormality
is very common in tropical areas with gene frequencies
typically ranging from 3 to 30%. The renewed interest in
malaria elimination, the rising concern that spread of
artemisinin-resistant falciparum malaria could derail
these elimination efforts and reverse recent substantial
gains in reducing malaria morbidity and mortality, and
the belated recognition that repeated relapse in vivax* Correspondence: nickw@tropmedres.ac
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unless otherwise stated.malaria is a major cause of morbidity (and in areas of
high transmission, mortality), have focused renewed at-
tention upon primaquine.
Search strategy and selection criteria
References were extracted from an extensive literature
search performed during a World Health Organization
(WHO) evidence review of 8-aminoquinoline safety [1].
References were identified through searches of NLM
PubMed for articles in English, French, Spanish, Italian,
and German using the terms ‘primaquine’, ‘pamaquine’,
‘plasmoquine’, ‘G6PD’ and ‘G6PD deficiency’ and the
limit ‘human’, with no time limit. Unpublished docu-
ments in the WHO archives and safety reports from the
Uppsala Monitoring Centre were also reviewed.
History
The first mass use of primaquine was in the Korean
War. Over 250,000 US soldiers received 14-day radical
curative regimens to eliminate long latency P. vivax in-
fections [2]. Since the 1950s, primaquine and, in the
Union of Soviet Socialist Republics (USSR), the closely
related quinocide, have been used extensively to prevent
seasonal long latency P. vivax, but the number of expo-
sures is unclear. In the 1970s, some 28 million people in
the Chinese Province of Jiangsu alone received mass pre-
ventive radical treatment regimens [3], which suggestsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been treated in the entire country. In Azerbaijan,
Tajikistan, Northern Afghanistan, and North Korea (DPR
Korea) approximately eight million people received mass
treatments with primaquine to prevent or eliminate P.
vivax infections. These treatments were supervised and
the population monitored for adverse events [4]. In
Nicaragua, 1.9 million people received a three day regi-
men of chloroquine and primaquine to control and elim-
inate vivax and falciparum malaria [5]. Although radical
five- to 14-day primaquine regimens have been recom-
mended widely for over 50 years in tropical regions
where P. vivax is prevalent, it is not known how many
treatments have been administered. Since the resurgence
of malaria in the early 1970s in India, which bears the
majority of the global burden of vivax malaria, there have
been approximately three million malaria cases reported
annually, over half caused by P. vivax [6].
As a gametocytocide in P. falciparum infections, only
one dose of primaquine is given (traditionally 0.5-
0.75 mg base/kg, recently reduced to 0.25 mg base/kg)
[7]. Again, although commonly recommended in Asia
and the Americas, it is uncertain how many millions
have received this treatment over the past 60 years.
Primaquine has been little used in the private sector, and
although it is a highly effective prophylactic and was
used weekly by the US military in the Vietnam War [8],
it has seldom been recommended to prevent malaria in
travellers. Thus despite administration of primaquine to
some 200 million people, arguments continue about
whether, when and how to give it!
Efficacy
The hypnozoitocidal activity of primaquine is predomin-
antly a function of total dose administered; 3.5 mg base/
kg (adult dose ~15 mg/day for 14 days) prevents >90%
of long latency P. vivax relapses, whereas twice the dose
(total 7 mg base/kg; adult dose 30 mg/day for 14 days) is
required for short latency frequently relapsing infections
in east Asia and Oceania. Poor adherence is an import-
ant cause of reduced effectiveness. There is no evidence
for acquired resistance to the liver stage activity. Both
the parasite burden (number of hypnozoites in the liver)
and degree of acquired immunity are important determi-
nants of the therapeutic response. Primaquine has potent
gametocytocidal activity in P. falciparum infections and
rapidly sterilizes the treated infection [9,10]. Provided a
drug with adequate asexual stage activity is given as well,
this substantially reduces onward transmission. In a recent
randomized, double-blind, placebo-controlled trial in
eastern Uganda, 468 children aged one to ten years
with uncomplicated falciparum malaria and normal G6PD
enzyme function (as assessed by the fluorescent spot test)
were randomized to receive artemether–lumefantrine,combined with either placebo or with a single dose of
0.1 mg/kg, 0.4 mg/kg, or 0.75 mg/kg primaquine base.
The mean duration of gametocyte carriage was 6.6 days
(95% CI 5.3-7.8) in the 0.75 mg/kg reference group,
6.3 days (5.1-7.5) in the 0.4 mg/kg primaquine group
(p = 0.74), 8.0 days (6.6-9.4) in the 0.1 mg/kg primaquine
group (p = 0.14), and 12.4 days (9.9-15.0) in the placebo
group (p <0.0001). Thus 0.4 mg/kg was non-inferior to
0.75 mg/kg [11], and 0.1 mg/kg occupied an interme-
diate position in the dose-response relationship. The
8-aminoquinolines are substantially more active in re-
ducing infectivity to mosquitos. Data from direct transmis-
sion blocking assessments from mosquito feeding studies
predict that, given together with an effective artemisinin
combination treatment (ACT), a single 0.25 mg base/kg
dose gives maximal gametocytocidal effects, and this is
now the recommended dose [7].
Toxicity
Dosing of primaquine is limited by abdominal discom-
fort at doses over 1 mg/kg. In general, primaquine is
well tolerated at individual doses ≤0.5 mg base/kg if
given together with food. Some methaemoglobinaemia is
common, but very seldom is dangerous. The main
adverse effect of primaquine is oxidant haemolysis.
Although some red cell loss may occur in normal sub-
jects, patients who are G6PD deficient are particularly
vulnerable. It is the potential for toxicity in G6PD defi-
ciency that has limited the use of primaquine. There are
over 180 different genetic G6PD variants, nearly all con-
ferring an unstable enzyme, which degrades more rap-
idly than the normal variant thereby rendering older red
cells vulnerable to oxidant damage [12,13]. The extent of
haemolysis depends on the degree of G6PD deficiency
and the dose and duration of exposure to primaquine.
Two of the most prevalent G6PD variants represent
ends of the severity spectrum with the Mediterranean
variant (the main variant found in Europe, west and cen-
tral Asia, and northern India) being amongst the most
profound deficiencies, and the African A- variant (found
in sub-Saharan Africa and in African-Americans) being
amongst the mildest. Severe haemolytic reactions can
still occur in G6PDA-, but they are much less frequent.
Haemolytic risks vary widely as there is also substantial
variability in G6PD activity between individuals with the
same genotype, and even within the same individual over
time. In less severe G6PD variants, primaquine-induced
haemolysis typically becomes evident after one or two
days’ exposure, when all the older erythrocytes’ oxidant
defences (mainly reduced glutathione) have been de-
pleted [14]. If primaquine is continued in subjects with
the African A- variant then haemolysis lessens, and the
haemoglobin starts to rise again despite further drug ad-
ministration, as reticulocytes enter the circulation to
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young red cells contain five times more G6PD than the
oldest red cells and so are relatively resistant to the
haemolytic effect. However, further haemolysis does
occur if higher doses of primaquine are given [16].
In contrast, in the severe Mediterranean variant, haem-
olysis continues if primaquine is not stopped and life-
threatening anaemia may result (Figure 1) [17,18].
Although the pathophysiology of primaquine haemolysis
was dissected in detail in classic studies conducted in
the 1950s and 1960s [14-20], several outstanding ques-
tions remain. Are patients with malaria at greater or
lesser risk of haemolysis than healthy subjects? Does
pre-existing hookworm or malaria-related anaemia re-
duce haemolysis? What exactly are the risks associated
with the different therapeutic regimens? What reduc-
tions in haemoglobin are life threatening? There are also
uncertainties over P. vivax relapse rates and latency in-
tervals across much of the tropics which complicate
therapeutic assessments, the methods for assessing
gametocytocidal effects and their interpretation in clin-
ical evaluations are disputed, and the community bene-
fits from deployment of primaquine as a single dose
gametocytocide have not been well characterized.
Safety
Deaths
Only 14 deaths associated with primaquine have been
reported over the past six decades of which 12 wereFigure 1 Primaquine-induced haemolysis in adults with different G6P
14 days at a dose of 30 mg/day in individuals with Mediterranean and Afri
[22,23]. The effects of a 45-mg single primaquine dose in individuals with e
This figure uses data derived from different studies as referenced.from severe haemolysis (one was due to hepatic necrosis,
and the cause of another was not stated) [1]. One fatality
may have followed a single 45-mg dose [25]. All the
other deaths followed multiple dose administrations.
Haemolytic adverse effects, but no deaths, were reported
from the mass treatments (MDA) in Jiangsu (>28 million
treated [3]) and from the combined experience in
Azerbaijan, Afghanistan, Tajikstan, and DPR Korea
(>eight million treated [4]). G6PD screening was not
performed during these MDAs but haemolysis was an-
ticipated, and so education was provided and health
services reinforced during the drug administrations. Ex-
cluding the Chinese data, the estimated risk for death
associated with primaquine from all these reports is one
in 621,428 with an upper 95% CI of one in 407,807. In-
cluding the Chinese data would make the risk four times
lower. The reported deaths occurred mainly in countries
with a minority of the global malaria burden, which does
raise concern about the generalizability of this estimate.
Severe adverse events
The most common severe adverse event (SAE) following
primaquine is severe intravascular haemolysis with dark
or black urine and mild jaundice. Allergic reactions and
neuropsychiatric symptoms have been reported rarely in
association with primaquine use. There are two serious
consequences of severe haemolysis; life-threatening an-
aemia and haemoglobinuric renal failure. From 69 stud-
ies and additional case reports (excluding the MDAD variants during daily dosing. Primaquine was given daily for
can A-variants [18,21] and 15 mg/day for Mahidol or Viangchan variants
ither Mahidol or Viangchan variants are shown for comparison [24].
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no SAEs were reported in G6PD-normal individuals,
with the possible exception of one psychotic reaction.
The 191 SAEs that were reported were in 25 individuals
likely to have been G6PD deficient, and in 166 with
proven G6PD deficiency (139 in case reports). The inci-
dence of SAEs in the known G6PD-deficient group was
11.2% (27/241). Of all SAEs, 11.5% occurred after a
probable overdose of primaquine, 75.9% with radical
curative regimens for vivax malaria and 12.6% after
administration of 30 or 45 mg primaquine in weekly
prophylactic or radical curative regimens, or as a single-
dose gametocytocide. Almost all the probable prima-
quine overdose (95.5%) SAEs were in children; most
from a single case series of 21 Sri Lankan children aged
two to 12 years hospitalized with acute intravascular
haemolysis. All those tested for G6PD activity (17
children) were deficient [26].
In the 12 MDA programmes, 27 SAEs were reported,
an estimated incidence of three SAEs per million. The
majority of the SAEs were haemolysis, giving an esti-
mated incidence of 1.8 episodes of severe haemolysis per
million people receiving radical curative regimens of
primaquine as MDA. In some MDA programmes given
to almost 300,000 people in Azerbaijan (where the
prevalence of G6PD deficiency, presumed Mediterranean
variant, varied between 0 and 38.7%) and Kunduz
Province, northern Afghanistan (Mediterranean variant
prevalence 5-10%), an interrupted regimen was used, de-
signed specifically so that haemolytic toxicity could be
detected and managed. This was 15 mg primaquine
(adult dose) once daily for four days, followed by three
days without drug, then primaquine for a further ten
days [27].
Haemolysis following single-dose primaquine
Haemolysis is self-limiting as primaquine is eliminated
rapidly (t1/2 ~ five hours). This is exploited in the once
weekly 0.75-mg base/kg radical cure regimen recom-
mended for patients with vivax malaria and ‘mild’ G6PD
variants [2,28], and the interrupted MDA regimens. Reti-
culocytosis following each dose compensates for haem-
olysis and the progressively younger red cell population
becomes increasingly resistant to primaquine’s haemo-
lytic effects. Few reports specifically examined the effect
of single-dose primaquine on anaemia in the treatment
of malaria, partly because malaria itself causes anaemia
with a similar time course to that caused by oxidant
haemolysis. Primaquine as a gametocytocide has usually
been recommended in areas of low transmission where
the haemoglobin nadir from malaria occurs around day
7. This coincides with the nadir following primaquine
haemolysis. Given that the usual dose recommended
(0.75 mg/kg) for the past 50 years was exactly the sameas that recommended weekly for radical cure in G6PD-
deficient patients [29], the risks have been assumed to
be very low (the newly recommended 0.25-mg/kg game-
tocytocidal dose is three times lower [7]). G6PD testing
has almost never been performed in this context. In
5,192 patients treated with mefloquine-sulphadoxine-
pyrimethamine and primaquine (45 mg, average weight
50 kg: 0.9 mg base/kg) on the northwestern border of
Thailand (G6PD-deficiency prevalence mainly Mahidol
variant ~10%) no fatalities and no serious haemolysis
was reported [30]. In a study in Tanzania, children
received artesunate-sulphadoxine-pyrimethamine and
0.75 mg/kg primaquine, and in 15 children who were
homo or hemizygous for G6PDA- deficiency there was a
mean [95% CI] fall in haemoglobin on day 7 of -2.5 g/dL
[-1.2 to -3.8 g/dL]. In one child, a G6PD A- heterozy-
gote, the haemoglobin concentration fell from 8.3 to
4.8 g/dL [31]. In Myanmar (G6PD-deficiency prevalence
10-20%), in a randomized comparison of different ACTs
in acute falciparum malaria, 397 patients received a sin-
gle 0.75 mg base/kg dose of primaquine. Overall 30% of
patients had pre-treatment haemoglobins <10 g/dL but
no serious haemolysis (Hb ≤5 g/dL) was observed [32].
In Sardinia 19 healthy individuals with presumed Medi-
terranean type G6PD deficiency were given primaquine
45 mg and chloroquine 300 mg; the median [range] fall
in haematocrit was 8% [6-19%] [18]. In Iran a single
primaquine 0.33 mg/kg dose was given with chloroquine
to six subjects with confirmed G6PD deficiency (likely
Mediterranean variant but not genotyped) without mal-
aria. All developed haemoglobinuria. The median [range]
haemoglobin reduction was 2.3 [0.7-3.4] g/dL. None re-
quired a blood transfusion [17]. In a recent randomized
trial of 468 Ugandan children with uncomplicated mal-
aria who received artemether-lumefantrine followed by a
single dose of primaquine 0.1, 0.4 or 0.75 mg/kg or pla-
cebo of whom 27% had some degree of G6PD deficiency,
no children developed symptomatic anaemia [33].
Dose-response relationship for haemolysis
Primaquine is metabolized in vivo via cytochrome P450
to reactive intermediates (mainly through CYP2D6)
thought to mediate both anti-malarial and haemolytic ef-
fects [34]. These active intermediates have not been
characterized definitively. Individuals with CYP2D6 gen-
etic polymorphisms conferring reduced enzyme activity
may have reduced primaquine efficacy [35,36]. The rela-
tionships between primaquine dose, duration and haemo-
lysis were characterized in detail for the G6PD A-variant
in healthy adult volunteers. A clear dose-response rela-
tionship was evident; increasing daily doses up to 45 mg
progressively shortened red cell survival (Figure 2) [21].
Dosing 45 mg daily could cause severe anaemia whilst
15 mg daily caused only mild anaemia. Taking 30 mg/day







51Cr Red cell half-life (days)
30mg 15mg <15mg45mg
Red cells remaining (%)
Figure 2 G6PD-deficient red cell survival following daily primaquine dosing. G6PD-deficient red cell survival was assessed by 51Cr labelling
and transfusion into G6PD-normal healthy recipients (15 mg/day or 45 mg single dose in Mahidol or Viengchan variants, 30 mg/day Mediterranean variant,
and a range of doses in African A- variant). The corresponding haematocrit reductions following continuous dosing (or in the green bar, a single dose)
in G6PD-deficient subjects are shown in the inset [17,21-24,37].
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mately the same degree of haemolysis as 15 mg/day in the
Mahidol or Viengchan variants, with no further decline in
haemoglobin during the second week of drug administra-
tion (Figure 1). These and other data are consistent with a
‘gene dosage’ effect as the African A- G6PD deficiency is
less severe than the Mahidol and Viengchan variants,
which in turn are less severe than the Mediterranean
variant.
Discussion and Conclusion
Primaquine is a very valuable anti-malarial drug, which
is under-used. Concerns over potentially dangerous
haemolytic toxicity along with the general unavailability
of a simple test to identify patients at risk have substan-
tially limited its deployment, and continue to do so. All
patients with malaria haemolyse and all G6PD-deficient
patients haemolyse additionally with primaquine treat-
ment. The extent of haemolysis depends on the dose,
duration and severity of deficiency. Whereas a single low
dose is very likely to be safe, daily primaquine dosing for
the radical cure of vivax malaria in a patient with severe
deficiency risks potentially life-threatening haemolysis.
Yet only 12 deaths from severe haemolysis have been
documented over the past 60 years [1]. More may have
gone unreported, although millions of people, many
thousands of whom must have had severe variants of
G6PD deficiency, received such regimens in MDAs with-
out reported loss of life. The most likely explanation issimply that MDA recipients who suddenly felt ill and
passed dark urine stopped taking primaquine.
For the physician contemplating radical curative treat-
ment of P. vivax or P. ovale malaria, the correct
approach is to test for G6PD deficiency. The NADPH
‘spot’ test identifies <30% of normal activity and should
therefore identify all G6PD male hemizygotes and most
female heterozygotes at high risk. Heterozygous females
are genetic mosaics due to random X chromosome in-
activation, also known as ‘Lyonisation’; as a consequence
they may by chance have a predominance of deficient
erythrocytes. Point-of-care tests with similar perform-
ance characteristics to the “spot test” have been devel-
oped recently [38]. For G6PD-deficient individuals the
recommended options are to withhold primaquine, or in
‘mild deficiency’ to give 0.75 mg/kg once weekly for
eight weeks. The once-weekly regimen was evaluated in
a relatively small number of adults with the A- variant,
and there is little published information on its use in
other G6PD variants (most of which are more severe
than A-). What should be recommended in the majority
of P. vivax-endemic areas where G6PD-deficiency test-
ing is not readily available? Multiple relapses cause sub-
stantial morbidity, interfering with development and
educational performance in children, causing abortion
and intra-uterine growth retardation in pregnancy and
contributing to life-threatening anaemia in young chil-
dren in higher transmission settings [39,40] When re-
lapse rates exceed 50% (e.g., in east Asia and Oceania),
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incidence of vivax malaria [41]. The benefits of radical
cure are substantial for all patients, while the risks of iat-
rogenic haemolytic anaemia are borne by the minority
who are G6PD deficient. If there is no available G6PD test
the correct approach to patient management depends on
the risks and the benefits i.e. the prevalence and severity
of G6PD deficiency in the area and the dose regimen re-
quired for radical cure, the degree of anaemia and the
availability of blood transfusion (i.e., the risk) as well as
the probability and health impact of relapses (the benefit).
For the malaria control programme manager consider-
ing recommending primaquine as a gametocytocide in
falciparum malaria, the assessment of risk is easier,
whilst that of benefit is more difficult. The currently rec-
ommended 0.25 mg/kg dose is 14 to 28 times lower than
the radical curative dose and two to three times lower
than previously recommended gametocytocidal doses
[7]. This low dose is associated with a red cell survival in
the G6PD A- variant five times longer than with the pre-
viously recommended 0.75 mg/kg dose. Given the infor-
mation on the safety of multiple dose radical cure, and
the documented effects of higher doses in G6PD-
deficient individuals, it seems highly unlikely that a sin-
gle 0.25 mg/kg dose poses any significant haemolytic
risk, even in individuals with severe G6PD deficiency.
G6PD testing is, therefore, considered unnecessary. As-
sessments of the transmission blocking dose-response
relationship based on indirect measures (gametocytae-
mia over time) provide an inconsistent and potentially
misleading picture [42], probably because these mea-
sures underestimate and correlate poorly with reduction in
infectivity [9,10]. Direct dose-response assessments of
infectivity to anopheline mosquito vectors suggest that
primaquine 0.25 mg base/kg produces maximum gameto-
cytocidal effects when given with an ACT [7]. The problem
is that the treatment provides benefit to the community
but no direct benefit to the treated patient. Whilst there is
indirect evidence that blocking transmission of treated
infections will reduce the incidence of malaria, proving it
directly (in large, cluster-randomized, community-based
trials) is very difficult. As transmission intensity increases
the asymptomatic transmission reservoir increases, and
the impact of reducing transmission in treated infections
is progressively diluted. It is unclear at what level of
transmission it is no longer “worth it” to give single dose
primaquine. The corollary is that as transmission is
reduced actively in an elimination programme every
transmission source must be removed. As the commu-
nity benefits depend on the proportion of patients who
are treated, every effort should be taken to ensure that
there is high coverage with single dose primaquine as a
gametocytocide. One barrier to achieving this is the lack
of availability of paediatric formulations.The usual medical response to uncertainty is caution.
However the struggle to contain and eliminate artemisinin-
resistant falciparum malaria is a race against time, with
potentially catastrophic consequences if we lose, so every
approach to preventing the transmission of artemisinin-
resistant parasites should be taken. It is essential to distin-
guish clearly the real risks of dangerous haemolytic
anaemia associated with radical curative regimens of
primaquine in vivax malaria from the considerably
lower risk associated with giving a single small dose in
falciparum malaria. This is why it is recommended that
a gametocytocidal dose of primaquine should be added
now to ACTs as part of regional elimination efforts [7].
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